Home / Pharmaceuticals / Treatment Resistant Depression Market By Drug Class (Tricyclic Antidepressants (TCAs), Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin Norepinephrine Reuptake Inhibitors (SNRIs), Monoamine Oxidase Inhibitors (MAOIs), Serotonin Neurotransmitter (5-HT2)-receptor Antagonists, Novel Agents) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2024

Treatment Resistant Depression Market By Drug Class (Tricyclic Antidepressants (TCAs), Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin Norepinephrine Reuptake Inhibitors (SNRIs), Monoamine Oxidase Inhibitors (MAOIs), Serotonin Neurotransmitter (5-HT2)-receptor Antagonists, Novel Agents) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2024

Published: Feb 2017 | Report Code: 58359-02-17

Prevalence of treatment resistant depression (TRD) appears to be substantial in the studied European nations and peaked in the 40-60 age group. Females had substantially higher disease burden, amounting to as much as twice as their male counterparts in certain age groups. According to treatment providers, patients with TRD have been found to be twice as likely as those with MDD to be hospitalized, with health care costs for hospitalized TRD patients being 5 to 6-fold higher than for non-TRD patients. Thus, TRD is major and comparatively most neglected public health issue, with an estimated 12 month prevalence of 2 to 3% for Stage 1 resistance and 1.5 to 2% for Stage 2.

For the purpose of this study, the global treatment resistant depression market is studied for the chief treatment drugs. Based on major drugs the treatment resistant depression market is classified into tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), serotonin neurotransmitter (5-HT2)-receptor antagonists, and novel agents (eg., mirtazapine, bupropion). Market size and forecast of each drug class is presented for the period 2014 to 2024 along with respective CAGR % for the forecast period 2016-2024.

Geographically, the global treatment resistant depression market is studied for the following regional markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East and Africa

The market size and forecast for the period 2014-2024 along with the CAGRs for the period 2016-2024 for the mentioned segments are also presented in this study.

Qualitative information sets such as market dynamics (drivers, challenges and opportunities) and market inclination insights are provided in this market assessment report. Tools such as competition assessment and attractive investment proposition are also included in this study for assessment of market competition. The report concludes with company profiles section that highlights key information about the major market players operating in the global treatment resistant depression market.

Treatment Resistant Depression Market

1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offering
1.2. Research Scope
1.3. Research Methodology
1.3.1. Research Methodology
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Assumptions

2. Executive Summary
2.1. Global Treatment Resistant Depression Market Portraiture
2.2. Global Treatment Resistant Depression, by Drug Type, 2015 & 2024 (Value %)
2.3. Global Treatment Resistant Depression, by Geography, 2015 (Value %)

3. Treatment Resistant Depression Market: Market Dynamics and Future Outlook
3.1. Global Treatment Resistant Depression Market Overview
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.1.1. Increasing prevalence of anxiety and depression related disorders in young adults
3.2.1.2. Rise in geriatric population
3.2.2. Challenges
3.2.2.1. Patent expiry of major antidepressants
3.2.2.2. Stigma related to treatment and acceptance of mental disorders and anxiety
3.2.3. Opportunities
3.2.3.1. Innovative therapies and strong pipeline
3.3. Attractive Investment Proposition
3.4. Competitive Analysis: Global Treatment Resistant Depression Market, 2015

4. Global Treatment Resistant Depression Market, By Drug Class, 2014–2024 (US$ Mn)
4.1. Overview
4.2. Tricyclic Antidepressants (TCAs)
4.3. Selective Serotonin Reuptake Inhibitors (SSRIs)
4.4. Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
4.5. Monoamine Oxidase Inhibitors (MAOIs)
4.6. Serotonin Neurotransmitter (5-HT2)-receptor Antagonists
4.7. Novel Agents

5. Global Treatment Resistant Depression Market, By Geography, 2014-2024 (US$ Mn)
5.1. Introduction
5.2. North America
5.2.1. U.S.
5.2.2. Canada
5.3. Europe
5.3.1. Germany
5.3.2. U.K.
5.3.3. Rest of Europe
5.4. Asia Pacific
5.4.1. China
5.4.2. Japan
5.4.3. Rest of Asia Pacific
5.5. Latin America (LATAM)
5.5.1. Brazil
5.5.2. Mexico
5.5.3. Rest of LATAM
5.6. Middle East and Africa (MEA)
5.6.1. UAE
5.6.2. Saudi Arabia
5.6.3. South Africa
5.6.4. Rest of MEA

6. Profiles
6.1. AstraZeneca plc
6.1.1. Business Description
6.1.2. Financial Information
6.1.3. Product Positions/Portfolio
6.1.4. News Coverage
6.2. Bristol-Myers Squibb
6.3. Eli Lilly and Company
6.4. Forest Laboratories (Allergan plc)
6.5. GlaxoSmithKline plc
6.6. Janssen Pharmaceuticals, Inc.
6.7. Pfizer, Inc.
6.8. Schering Plough Corporation
6.9. Vistagen Therapeutics, Inc.
6.10. Wyeth

Based on the used drug classes, the global treatment resistant depression market is classified as:

  • Tricyclic antidepressants (TCAs)
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
  • Monoamine Oxidase Inhibitors (MAOIs)
  • Serotonin Neurotransmitter (5-HT2)-receptor Antagonists
  • Novel Agents (eg., mirtazapine, bupropion)

Treatment Resistant Depression Market

Antidepressant drugs in treatment resistant depression may vary from country to country, generally SSRIs are prescribed as a first line therapy, followed by SNRIs. SSRIs are the first choice drug for the treatment of depression because these are most safe and effective class of drug as comparative other class of antidepressant medication. SNRIs are choice of the drug to treat depression, as there is no potential for addiction with this class of drugs. Market growth of SNRIs largely driven by Fetzima and Pristiq. Fetzima approved in 2013, provides a more balanced reuptake of both serotonin and norepinephrine, 1:2. Fetzima (Levomilnacipran) is available as a branded drug only, a generic version is not yet available. TCAs are earliest approved antidepressant, but TCAs tend because more side effects. TCAs are considered a second-line treatment to newer drugs like SSRIs/SNRIs and atypical antidepressants.

Based on geographical segmentation, the global treatment resistant depression market is studied for:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Rest of Asia-Pacific
    • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
  • Rest of Middle East and Africa

Treatment Resistant Depression Market

This report presents the cumulative market size for each mentioned regional and individual country-level markets for treatment resistant depression. At present, North America and Europe lead the global market in terms of revenue. Government guidelines for diagnosis and treatment of MDD along with significant population with MDD and TRD are the prime contributors to the dominance of these regions. Asia Pacific will witness the fastest market growth during the forecast period owing to growing awareness, rapid evolution of healthcare infrastructure and flourishing medical tourism industry in the region. Awareness about the proven benefits of use of antidepressant combinations will further support the growth of treatment resistant depression market in Asia Pacific and Middle East and Africa markets.

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients